E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systemic sclerosis associated with interstitial lung disease. |
Esclerosis sistémica asociada a enfermedad pulmonar intersticial. |
|
E.1.1.1 | Medical condition in easily understood language |
Systemic sclerosis is a disease characterized by abnormal and excess fibrosis, a hardening of tissues and organs. |
La esclerosis sistémica es una enfermedad caracterizada por alteraciones y exceso de fibrosis, un endurecimiento de los tejidos y órganos. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025109 |
E.1.2 | Term | Lung involvement in systemic sclerosis |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To assess the safety and tolerability of PRA023 in SSc-ILD. • To compare the annual rate of change from Baseline in forced vital capacity (FVC), of PRA023 vs. placebo over 50 weeks. |
• Evaluar la seguridad y la tolerabilidad de PRA023 en sujetos con ES-EPI. • Comparar la tasa anual de variación con respecto al momento basal de la capacidad vital forzada (FVC), entre PRA023 y placebo durante 50 semanas. |
|
E.2.2 | Secondary objectives of the trial |
• To compare the change from Baseline in FVC at Week 50. • To compare the change from Baseline in high-resolution computer tomography (HRCT) at Week 50. • To compare the annual rate of change in percent predicted FVC. • To compare proportion of subjects with an improvement in the American College of Rheumatology Combined Response Index in Systemic Sclerosis (ACR CRISS) score at Week 50. |
• Comparar la variación con respecto al momento basal de la FVC en la semana 50. • Comparar la variación con respecto al momento basal en tomografía computarizada de alta resolución (TCAR) en la semana 50. • Comparar la tasa anual de variación en porcentaje de valor teórico de la FVC. • Comparar la proporción de sujetos con mejoría en la puntuación ACR CRISS (Índice de respuesta combinada en la esclerosis sistémica del American College of Rheumatology) en la semana 50. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Skin Biopsy Substudy: to assess change in histology and protein expression. Pharmacokinetic Substudy: fully characterize PK of PRA023 in subjects with SSc-ILD. |
Subestudio de biopsia cutánea: para evaluar el cambio en la histología y la expresión de proteínas. Subestudio farmacocinético: caracterizar completamente la farmacocinética de PRA023 en sujetos con SSc-ILD. |
|
E.3 | Principal inclusion criteria |
1. Confirmed diagnosis of systemic sclerosis with onset of disease < or = 5 years ago. 2. Diffuse cutaneous scleroderma. 3. Systemic sclerosis related to interstitial lung disease confirmed by HRCT. 4. FVC > or = 45% of predicted normal. 5. Diffusing capacity of lung for carbon monoxide (DLCO) > or = 45% of predicted normal. 6. Stable dosing of myocphenolate mofetil (MMF), methotrexate (MTX) or azathioprine, as well as corticosteroids. 7. Able to provide written informed consent and understand and comply with the requirements of the study. |
1. Diagnóstico confirmado de esclerosis sistémica con aparición de la enfermedad < o = hace 5 años. 2. Esclerodermia cutánea difusa. 3. Esclerosis sistémica relacionada con enfermedad pulmonar intersticial confirmada mediante TCAR. 4. FVC > o = 45% de lo normal previsto. 5. Capacidad de difusión pulmonar del monóxido de carbono (DLCO) > o = 45% del valor teórico normal. 6. Dosis estable de micofenolato mofetilo (MMF), metotrexato (MTX) o azatioprina, así como corticoides. 7. Capacidad de otorgar el consentimiento informado por escrito y de comprender y cumplir con los requisitos del estudio. |
|
E.4 | Principal exclusion criteria |
1. WOCBP and men with female partners of childbearing potential who are unwilling or unable to use tow highly effective methods of contraception to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of study drug. 2. Airway obstruction per pulmonary function test (PFT) or clinically significant pulmonary arterial hypertension. 3. Current clinical diagnosis of another inflammatory connective tissue disease. 4. Any active infections, a serious infection within the past 3 months, or chronic bacterial infection. 5. Current smoker or smoking within 6 months of screening. 6. Subjects in the opinion of the investigator that are at an unacceptable risk for participation in the study. 7. Subjects who meet the protocol criteria for important laboratory exclusion criteria. |
1. MEF y varones con parejas en edad fértil que no se muestren dispuestos o no puedan utilizar dos métodos anticonceptivos muy eficaces para evitar el embarazo durante todo el período del estudio y hasta 12 semanas después de la última dosis del fármaco del estudio. 2. Obstrucción de las vías respiratorias por prueba de función pulmonar (PFT) o hipertensión arterial pulmonar clínicamente significativa. 3. Diagnóstico clínico actual de otra enfermedad inflamatoria del tejido conjuntivo. 4. Cualquier infección activa, una infección grave en los últimos 3 meses o una infección bacteriana crónica. 5. Fumador actual o fumador en los 6 meses previos a la selección. 6. Sujetos para los que, en opinión del investigador, suponga un riesgo inaceptable la participación en el estudio. 7. Sujetos que cumplan con los criterios del protocolo para criterios importantes de exclusión de laboratorio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
_ The proportion of subjects reporting adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and markedly abnormal laboratory values. _ To compare the annual rate of change from Baseline in FVC. |
_ Proporción de sujetos que informaron eventos adversos (AE), eventos adversos graves (SAE), AEs que llevaron a la interrupción y valores de laboratorio marcadamente anormales. _ Comparar la tasa anual de variación desde el momento basal de la FVC. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
_To compare the change from Baseline in FVC. _To compare the annual rate of change in percent predicted FVC. _To compare the change from Baseline in HRCT. _To compare proportion of subjects with an improvement of the ACR CRISS score. |
_Comparar la variación con respecto al momento basal de la FVC. _Comparar la tasa anual de variación en porcentaje de valor teórico de la FVC. _Comparar la variación con respecto al momento basal en tomografía computarizada de alta resolución (TCAR). _Comparar la proporción de sujetos con mejoría en la puntuación ACR CRISS. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 39 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
France |
Germany |
Hungary |
Israel |
Italy |
Netherlands |
Norway |
Poland |
Spain |
Switzerland |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 3 |